Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology

Abstract:
Xagenic Inc., one of MaRS Innovation's (MI) portfolio investments, was awarded $1-million in funding by Ontario's Ministry of Research and Innovation (MRI) through its Investment Accelerator Fund-Life Sciences (IAF-LS) program. The announcement was made at MaRS by Research and Innovation Minister Glen Murray.

Provincial Investment Supports Commercialization of Leading-Edge Molecular Diagnostic Screening Technology

Toronto, Canada | Posted on July 26th, 2011

"Today's announcement will go a long way in helping us to commercialize a technology that will ultimately shape the future of diagnostic testing - instead of waiting days for results, doctors and patients will only need to wait minutes," said Dr. Shana Kelley, Founder of Xagenic Inc. and Professor from the Leslie Dan Faculty of Pharmacy and the Faculty of Medicine at the University of Toronto.

Xagenic has pioneered a revolutionary class of chip-based molecular diagnostics. Using a breakthrough in engineering matter at the nanoscale, Xagenic employs its patented nanostructured microelectrodes to achieve highly sensitive nucleic acid sensors that detect DNA and RNA at record-breaking speed. The diagnostic screening technology was developed at the University of Toronto.

Unlike existing molecular tests which are complex, time-consuming and require skilled laboratory technicians, the Xagenic technology enables faster detection of pathogens -- in less than 30 minutes. For patients, faster diagnosis of conditions (ranging from infectious disease to cancer) can mean less anxiety and faster treatment decisions. For Ontario's strained health care system, the accurate and rapid technology will enable more efficient, on-site detection of pathogens in the comfort of a physician's office or by the patient's bedside.

"We're thrilled that the Ministry of Research and Innovation shares our vision to bring to market Xagenic's innovative technology. Xagenic is a prime example of how MaRS Innovation and its member institutions can turn a powerful idea into reality and deliver tangible benefits to patient care as well as fuel the knowledge economy," said Rafi Hofstein, CEO of MI and Xagenic Inc.

"We're proud of Ontario's creative environment. Our highly skilled workforce, world-class education system and internationally recognized research community are all second to none. Our government invests in innovative companies like Xagenic so that our province's best ideas can flourish, create jobs and improve the lives of Ontarians, now and in the future," said Glen Murray, Minister of Research and Innovation and MPP for Toronto Centre.

In its first year of operation, Toronto-based Xagenic Inc. secured investments totalling more than

$1-million from key organizations representing the research and commercialization community: MI, the Ontario Institute for Cancer Research, the Ontario Centre of Excellence (OCE) and The Health Technology Exchange. Today's provincial funding and an additional $200,000 commitment by OCE's Centre for Commercialization of Research brings Xagenic's total amount of secured investments to more than

$2.2-million. Xagenic's establishment and the significant amount of investment raised in its first year of operation reflects MI's leadership in identifying and nurturing exciting inventions and ideas towards the marketplace.

####

About Xagenic Inc.
Founded in 2010 and based in Toronto, life sciences company Xagenic Inc. is pioneering a leading-edge, chip-based diagnostic screening technology that uses nanotechnology-based microelectrodes. This technology, invented at the University of Toronto by renowned scientist and Professor Dr. Shana Kelley, is being developed to address a large clinical unmet need: rapid, on-demand, sample-to-answer detection of pathogens in less than 30 minutes.

About MaRS Innovation
MaRS Innovation provides an integrated commercialization platform that harnesses the economic potential of the exceptional discovery pipeline of 16 leading Toronto academic institutions. MaRS Innovation is a non-profit organization with an independent industry-led Board of Directors, funded through the Government of Canada's Networks of Centres of Excellence and contributions of its member institutions. Designed to enhance the commercial output of Toronto's outstanding scientific research cluster, MaRS Innovation will make a significant contribution to Canada's economic outlook and the quality of life for Canadians and others around the world. MaRS Innovation will advance commercialization through industry partnerships, licensing and company creation. The MaRS Innovation mission is to put Canada on the global innovation stage, by better connection research with industry and strengthening Canada's competitive capacity in knowledge based business - in short, to launch and new generation of robust, high-growth Canadian companies that will become global market leaders. For more information, visit www.marsinnovation.com

About The Investment Accelerator Fund-Life Sciences Program
The Investment Accelerator Fund-Life Sciences (IAF-LS) helps accelerate the growth of life sciences companies in Ontario. The fund invests up to $1,000,000 in seed and later stage financing in companies that have the potential to be global leaders in their field and provide sustainable economic benefits to Ontario. Funded by the Government of Ontario, the fund is a $7-million program that helps innovative life sciences companies turn their discoveries into new products and services that meet patient needs. The IAF-LS is delivered by MaRS . For more information, please visit www.marsdd.com/iaf-lifesciences

About The Ontario Centres of Excellence's Centre for Commercialization of Research
Ontario Centres of Excellence (OCE) Inc. drives the commercialization of cutting-edge research across key market sectors to build the economy of tomorrow and secure Ontario's global competitiveness. In doing this, OCE fosters the training and development of the next generation of innovators and entrepreneurs and is a key partner with Ontario's industry, universities, colleges, research hospitals, investors and governments. A champion of leading-edge technologies, best practices and research, Ontario Centres of Excellence invests in sectors such as advanced health, digital media and information communications, advanced manufacturing and materials, and cleantech including energy, environment and water. Ontario Centres of Excellence is a key partner in delivering Ontario's Innovation Agenda as a member of the province's Ontario Network of Excellence (ONE). Funded by the Government of Ontario, the ONE is Ontario's innovation system. The ONE is made up of regional and sector focused organizations designed to help Ontario-based entrepreneurs rapidly grow their companies, and create jobs. For more information visit oneinnovation.ca.

Ontario Centres of Excellence through its Centre for Commercialization of Research (CCR), an initiative supported by the federal government, also acts as a catalyst which allows innovative businesses to grow and achieve sustainable commercial success and global competitiveness. OCE's Centre for Commercialization of Research is supported by the federal government through a Networks of Centres of Excellence Program.

Contacts:
Media Contact
Rafi Hofstein
President & CEO
MaRS Innovation and Xagenic Inc.
647.260.7868 or

Copyright © http://www.xagenic.com/

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Researchers develop artificial building blocks of life March 8th, 2024

How surface roughness influences the adhesion of soft materials: Research team discovers universal mechanism that leads to adhesion hysteresis in soft materials March 8th, 2024

Two-dimensional bimetallic selenium-containing metal-organic frameworks and their calcinated derivatives as electrocatalysts for overall water splitting March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Graphene Flagship start-up Bedimensional closes a second €10 million investment round February 10th, 2023

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

180 Degree Capital Corp. Reports +6.7% Growth in Q4 2020, $9.28 Net Asset Value per Share as of December 31, 2020, and Developments from Q1 2021 Including Expected Investment in a Planned SPAC Sponsor February 22nd, 2021

Govt.-Legislation/Regulation/Funding/Policy

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Researchers’ approach may protect quantum computers from attacks March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Optically trapped quantum droplets of light can bind together to form macroscopic complexes March 8th, 2024

Nanomedicine

High-tech 'paint' could spare patients repeated surgeries March 8th, 2024

Researchers develop artificial building blocks of life March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Sensors

$900,000 awarded to optimize graphene energy harvesting devices: The WoodNext Foundation's commitment to U of A physicist Paul Thibado will be used to develop sensor systems compatible with six different power sources January 12th, 2024

A color-based sensor to emulate skin's sensitivity: In a step toward more autonomous soft robots and wearable technologies, EPFL researchers have created a device that uses color to simultaneously sense multiple mechanical and temperature stimuli December 8th, 2023

New tools will help study quantum chemistry aboard the International Space Station: Rochester Professor Nicholas Bigelow helped develop experiments conducted at NASA’s Cold Atom Lab to probe the fundamental nature of the world around us November 17th, 2023

TU Delft researchers discover new ultra strong material for microchip sensors: A material that doesn't just rival the strength of diamonds and graphene, but boasts a yield strength 10 times greater than Kevlar, renowned for its use in bulletproof vests November 3rd, 2023

Announcements

What heat can tell us about battery chemistry: using the Peltier effect to study lithium-ion cells March 8th, 2024

Curcumin nanoemulsion is tested for treatment of intestinal inflammation: A formulation developed by Brazilian researchers proved effective in tests involving mice March 8th, 2024

The Access to Advanced Health Institute receives up to $12.7 million to develop novel nanoalum adjuvant formulation for better protection against tuberculosis and pandemic influenza March 8th, 2024

Nanoscale CL thermometry with lanthanide-doped heavy-metal oxide in TEM March 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project